-
Featured Authors
Inside BIO
- Big Red Biotech blog
- Biocentury
- BiotechBlog
- Bruce Booth
- Fierce Biotech
- Get the Facts from Farmer Gene
- GMO Pundit
- Harvest Public Media
- In Vivo Blog
- Industrial Biotechnology and Climate Change
- Partnership to Improve Patient Care
- Patent Baristas
- Patently BIOtech
- Pharmalot
- Xconomy – Life Sciences
- YouTube – The BIOchannel
Category Archives: Inside BIO Industry Analysis
Biotech IPO Window – Still Ajar?
IPO plans for Quark Pharmaceuticals were officially put on hold last week as markets continue to drop and investors shy away from risk. This is the fifth IPO withdrawal since June. Ambit, Agendia and Clarus cited market reasons for their withdrawals, and Advanced BioHealing sought a higher valuation exit via acquisition. Only one biotech IPO, Horizon Pharma, has made it out in the last six months. Of the nine biotech IPOs so far in 2011, Read More >
BioWorld previews BIO India: India Emerges as Global Player via Multinational Partnering
BioWorld’s Tom Wall interviewed BIO’s Alan Eisenberg (subscription required) on what attendees can expect at this week’s BIO India International Partnering Conference. Interest in India has been strong and attendance at the conference is expected to surpass last year’s event. The population forecasted to grow in the coming years, combined with significant disease burden is a draw for many companies seeking business development and partnering opportunities. BIO India will feature keynote speakers Glenn Saldanha, Chairman Read More >
The Burrill Report: Pushing Policies in a Changed Washington
The Burrill Report’s Daniel Levine talks to BIO’s Alan Eisenberg regarding recent fluctuations in the financial markets and the impact on public policy. Eisenberg discusses implementation of BIO’s legislative proposals and the outlook for the industry. BIO will be hosting the BIO Investor Forum to bring together industry leaders to discuss these recent developments that could have a major influence in helping to shape the future of biotechnology.
2011 BIO International Convention: The evolution of one-on-one partnering
From the beginning, networking has been a central focus at BIO’s events. Our members attend our conferences primarily to seek out business opportunities and to meet other biotech executives. When company presentations were introduced at the 1998 BIO International Convention, delegates registered for the conference by mail and fax and presentations were the key means for companies to tell their stories at BIO’s early events. With BIO members asking for introductions to pharmaceutical companies, BIO Read More >
Three dealmaking trends to look for in 2011
The relationship between the biotechnology and pharmaceutical industries has never been clearer – partner to survive. The Business Forum at the 2011 BIO International Convention is the world’s largest venue for partnering and it might be the best way for emerging companies to find partners . While there are many quality sources for historical deal-trends, the Campbell Alliance and BIO have created the Dealmakers’ Intentions Survey and the BIO One-on-One Partnering Forecast, two unique forward-looking, Read More >
